증후군 성감염증 검사 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Syndromic Infectious Disease Testing Market Summary

The global syndromic infectious disease testing market size was valued at USD 4.7 billion in 2025 and is projected to grow from USD 5.0 billion in 2026 to USD 7.1 billion by 2033, at a CAGR of 5.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.1% in 2025. Market growth is primarily driven by the increasing adoption of rapid multiplex molecular diagnostics to enable timely clinical decision-making, as healthcare providers increasingly require faster, more comprehensive identification of infectious pathogens.

Syndromic testing enables the simultaneous detection of multiple bacterial, viral, fungal, and parasitic targets associated with a defined clinical syndrome.

Syndromic testing helps clinicians shorten diagnostic turnaround times and initiate more appropriate treatment strategies.

Global Syndromic Infectious Disease Testing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends and opportunities in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global syndromic infectious disease testing market report based on the product, technology, application, end use, and region.

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Instruments
• Assay Kits, Reagents & Consumables
• Software & Informatics
• Laboratory Testing Services
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Multiplex PCR/RT-PCR
• Multiplex Isothermal Amplification
• Other Multiplex Molecular Technologies
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Respiratory Infections (Including Pneumonia)
• Gastrointestinal Infections
• Bloodstream Infections
• Meningitis & Encephalitis
• Sexually Transmitted Infections
• Tropical & Febrile Illnesses
• Other Infectious Syndromes
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Reference Laboratories
• Public Health Laboratories
• Academic & Research Institutions
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Application Segment
  • 1.2.4. End use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Syndromic Infectious Disease Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing adoption of rapid multiplex molecular diagnostics for timely infectious disease diagnosis
    • 3.2.1.2. Rising burden of infectious diseases and antimicrobial resistance (AMR)
    • 3.2.1.3. Expansion of infectious disease surveillance and laboratory modernization initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of multiplex molecular testing platforms and proprietary consumables
    • 3.2.2.2. Complex regulatory approval requirements and limited reimbursement coverage
  • 3.2.3. Market opportunity analysis
• 3.3. Global Syndromic Infectious Disease Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Syndromic Infectious Disease Testing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Syndromic Infectious Disease Testing Market Product Movement Analysis
• 4.3. Global Syndromic Infectious Disease Testing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts, 2021 to 2033, (USD Billion)
• 4.5. Assay Kits, Reagents & Consumables
  • 4.5.1. Assay Kits, Reagents & Consumables market estimates and forecasts, 2021 to 2033, (USD Billion)
• 4.6. Software & Informatics
  • 4.6.1. Software & Informatics market estimates and forecasts, 2021 to 2033, (USD Billion)
• 4.7. Laboratory Testing Services
  • 4.7.1. Biopsy market estimates and forecasts, 2021 to 2033, (USD Billion)

Chapter 5. Global Syndromic Infectious Disease Testing Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Syndromic Infectious Disease Testing Market Technology Movement Analysis
• 5.3. Global Syndromic Infectious Disease Testing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Billion)
• 5.4. Multiplex PCR/RT-PCR
  • 5.4.1. Multiplex PCR/RT-PCR market estimates and forecasts, 2021 to 2033, (USD Billion)
• 5.5. Multiplex Isothermal Amplification
  • 5.5.1. Multiplex Isothermal Amplification market estimates and forecasts, 2021 to 2033, (USD Billion)
• 5.6. Other Multiplex Molecular Technologies
  • 5.6.1. Other Multiplex Molecular Technologies market estimates and forecasts, 2021 to 2033, (USD Billion)

Chapter 6. Global Syndromic Infectious Disease Testing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Syndromic Infectious Disease Testing Market Application Movement Analysis
  • 6.2.1. Global Syndromic Infectious Disease Testing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
• 6.3. Respiratory Infections (Including Pneumonia)
  • 6.3.1. Respiratory Infections (Including Pneumonia) market estimates and forecasts, 2021 to 2033, (USD Billion)
• 6.4. Gastrointestinal Infections
  • 6.4.1. Gastrointestinal Infections market estimates and forecasts, 2021 to 2033, (USD Billion)
• 6.5. Bloodstream Infections
  • 6.5.1. Bloodstream Infections market estimates and forecasts, 2021 to 2033, (USD Billion)
• 6.6. Meningitis & Encephalitis
  • 6.6.1. Meningitis & Encephalitis market estimates and forecasts, 2021 to 2033, (USD Billion)
• 6.7. Sexually Transmitted Infections
  • 6.7.1. Sexually Transmitted Infections market estimates and forecasts, 2021 to 2033, (USD Billion)
• 6.8. Tropical & Febrile Illnesses
  • 6.8.1. Tropical & Febrile Illnesses market estimates and forecasts, 2021 to 2033, (USD Billion)
• 6.9. Other Infectious Syndromes
  • 6.9.1. Other Infectious Syndromes market estimates and forecasts, 2021 to 2033, (USD Billion)

Chapter 7. Global Syndromic Infectious Disease Testing Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Syndromic Infectious Disease Testing Market End Use Movement Analysis
  • 7.2.1. Global Syndromic Infectious Disease Testing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
• 7.3. Hospitals
  • 7.3.1. Hospitals market estimates and forecasts, 2021 to 2033, (USD Billion)
• 7.4. Diagnostic Laboratories
  • 7.4.1. Diagnostic Laboratories market estimates and forecasts, 2021 to 2033, (USD Billion)
• 7.5. Reference Laboratories
  • 7.5.1. Reference Laboratories market estimates and forecasts, 2021 to 2033, (USD Billion)
• 7.6. Public Health Laboratories
  • 7.6.1. Public Health Laboratories market estimates and forecasts, 2021 to 2033, (USD Billion)
• 7.7. Academic & Research Institutions
  • 7.7.1. Academic & Research Institutions market estimates and forecasts, 2021 to 2033, (USD Billion)
• 7.8. Others
  • 7.8.1. Others market estimates and forecasts, 2021 to 2033, (USD Billion)

Chapter 8. Syndromic Infectious Disease Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2021 to 2033, (USD Billion)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts, 2021 to 2033, (USD Billion)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts, 2021 to 2033, (USD Billion)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts, 2021 to 2033, (USD Billion)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts, 2021 to 2033, (USD Billion)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts, 2021 to 2033, (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2025
• 9.4. List of Key Certification Providers/Scheme Owners
• 9.5. Company Profiles/Listing
  • 9.5.1. Abbott
    • 9.5.1.1. Company overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. bioMerieux SA
    • 9.5.2.1. Company overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. QIAGEN
    • 9.5.3.1. Company overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. BD
    • 9.5.4.1. Company overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Danaher Corporation
    • 9.5.5.1. Company overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. F. Hoffmann-La Roche Ltd
    • 9.5.6.1. Company overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Seegene Inc.
    • 9.5.7.1. Company overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. DiaSorin S.p.A.
    • 9.5.8.1. Company overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. Thermo Fisher Scientific Inc.
    • 9.5.9.1. Company overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. Hologic, Inc.
    • 9.5.10.1. Company overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives